MAIN STORY
A meaningful trial signal, not the final answer
AbbVie said on October 22 that about 1,400 people took part in its late-stage lutikizumab study. The headline outcome was the proportion achieving a reduction of at least 75% in inflammatory nodules and abscesses at week 16. Approximately 31% on treatment reached that threshold compared with 23% on placebo. The absolute difference of eight percentage points supports the company’s claim that the primary endpoint was met, although it provides only part of the clinical picture.
HS is not ordinary acne, nor is it contagious or caused by poor hygiene. Lesions often develop in the armpits, groin and other areas of friction, and can recur with tunnels, discharge and scarring. People may live with pain and social isolation for years before receiving a diagnosis. For them, a useful new medicine must offer sustainable improvement in daily life, not simply move one trial measure.
Lutikizumab remains an investigational HS treatment. Detailed adverse-event data, durability and outcomes across different patient groups deserve scrutiny when full results become available. Statistical significance and the size of a benefit experienced by a particular patient are different questions.

















